David Esposito is an experienced health care executive who has built and scaled multiple companies, resulting in successful exits to strategic buyers. He is the former CEO of Armune BioScience, where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.

David was president of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. He began his career as a sales representative with Merck & Co. Inc., rising through the ranks of sales, marketing and commercial strategy for the U.S. division.

As a combat veteran, David led an infantry platoon with the 101st Airborne Division through several combat operations and was recognized with a Bronze Star for combat action in Iraq in 1991. He earned his bachelor’s degree in civil engineering from the U.S. Military Academy at West Point and his MBA from Syracuse University.